Propranolol for infantile hemangiomas: Our preliminary experience

Abstract

Objective: Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas. This study explores the impact of propranolol on infantile hemangiomas. Study Design : Prospective study Materials and Methods: Propranolol was given to 38 children (21 girls and 17 boys) propranolol was administered with a dose of 2mg/kg per day, given in 2 or 3 divided doses. Children between age 3 weeks to 12 weeks included in study. Oral propranolol given between February 2013 to January 2014. Serial photographs taken at 6-8 weeks interval during the course of their therapy to record clinical response. Results: thirty eight children with complete photo documentation were treated with oral propranolol for infantile hemangiomas between February 2013 to January 2014.Out of 38 patient 36 patients showed improvement in their hemangiomas by effects on color and rapid/progressive reduction in size during propranolol therapy. Lesions were determined as complete resolution (n -3, 7.5%), ongoing resolution (n -33, 86.8%), or no sign of resolution ie no response (n - 2, 5%). No serious side effects of propanolol were observed in any patients. Conclusion: Propranolol may revolutionize the treatment of hemangiomas . At therapeutic doses (2mg/kg/day) , propranolol is safe and effective in the treatment of infantile haemangiomas.